Does AFATINIB Cause Malignant neoplasm progression? 1,622 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,622 reports of Malignant neoplasm progression have been filed in association with AFATINIB (Gilotrif). This represents 26.7% of all adverse event reports for AFATINIB.
1,622
Reports of Malignant neoplasm progression with AFATINIB
26.7%
of all AFATINIB reports
445
Deaths
283
Hospitalizations
How Dangerous Is Malignant neoplasm progression From AFATINIB?
Of the 1,622 reports, 445 (27.4%) resulted in death, 283 (17.4%) required hospitalization, and 48 (3.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for AFATINIB. However, 1,622 reports have been filed with the FAERS database.
What Other Side Effects Does AFATINIB Cause?
Diarrhoea (2,001)
Rash (808)
Stomatitis (468)
Death (443)
Nausea (430)
Decreased appetite (412)
Vomiting (381)
Paronychia (344)
Dehydration (323)
Fatigue (256)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which AFATINIB Alternatives Have Lower Malignant neoplasm progression Risk?
AFATINIB vs AFINITOR
AFATINIB vs AFLIBERCEPT
AFATINIB vs AGALSIDASE ALFA
AFATINIB vs AGALSIDASE BETA
AFATINIB vs AGOMELATINE